[go: up one dir, main page]

PE20150644A1 - Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno - Google Patents

Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno

Info

Publication number
PE20150644A1
PE20150644A1 PE2015000095A PE2015000095A PE20150644A1 PE 20150644 A1 PE20150644 A1 PE 20150644A1 PE 2015000095 A PE2015000095 A PE 2015000095A PE 2015000095 A PE2015000095 A PE 2015000095A PE 20150644 A1 PE20150644 A1 PE 20150644A1
Authority
PE
Peru
Prior art keywords
androgen receptor
methods
modified
compositions
receptor polypeptides
Prior art date
Application number
PE2015000095A
Other languages
English (en)
Inventor
James David Joseph
Jeffrey H Hager
John Lee Sensintaffar
Nhin Lu
Jing Qian
Nicholas D Smith
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of PE20150644A1 publication Critical patent/PE20150644A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/5759—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)

Abstract

La invencion describe polipeptidos del receptor de androgeno modificado que son resistentes a la inhibicion por un inhibidor del receptor de androgeno. En la invencion se describen composiciones, combinaciones y estuches que contienen los polipeptidos del receptor de androgeno modificados y metodos de uso de los polipeptidos del receptor de androgeno modificados. En la invencion se describen, ademas, metodos de uso de los polipeptidos del receptor de androgeno modificados como agentes de analisis para la identificacion y el diseno de moduladores del receptor de androgeno de tercera generacion. En la invencion se describen, ademas, moduladores del receptor de androgeno de tercera generacion que inhiben la actividad de los polipeptidos del receptor de androgeno modificados. Se describen, ademas, composiciones farmaceuticas y medicamentos que incluyen los compuestos que se describen en la invencion, asi como tambien metodos de uso de tales moduladores del receptor de androgeno, solos y en combinacion con otros compuestos, para el tratamiento de enfermedades o condiciones, lo que incluye a los canceres, tales como los canceres de prostata resistentes a la castracion, que son mediados o dependientes de los receptores de androgeno
PE2015000095A 2012-07-27 2013-07-26 Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno PE20150644A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676842P 2012-07-27 2012-07-27
US201361783763P 2013-03-14 2013-03-14
US201361829123P 2013-05-30 2013-05-30

Publications (1)

Publication Number Publication Date
PE20150644A1 true PE20150644A1 (es) 2015-05-11

Family

ID=48948536

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2015000095A PE20150644A1 (es) 2012-07-27 2013-07-26 Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno
PE2019000439A PE20190574A1 (es) 2012-07-27 2013-07-26 Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno
PE2019001034A PE20190845A1 (es) 2012-07-27 2013-07-26 Metodos para determinar resistencia a terapia de receptor de androgeno

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2019000439A PE20190574A1 (es) 2012-07-27 2013-07-26 Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno
PE2019001034A PE20190845A1 (es) 2012-07-27 2013-07-26 Metodos para determinar resistencia a terapia de receptor de androgeno

Country Status (34)

Country Link
US (2) US9617602B2 (es)
EP (2) EP2877599B1 (es)
JP (3) JP6297556B2 (es)
KR (2) KR102210183B1 (es)
CN (3) CN110845626A (es)
AU (3) AU2013295543B2 (es)
BR (2) BR112015001801A2 (es)
CA (1) CA2879926A1 (es)
CL (1) CL2015000194A1 (es)
CO (1) CO7280477A2 (es)
CR (1) CR20150022A (es)
CY (1) CY1122651T1 (es)
DK (1) DK2877599T3 (es)
EA (2) EA029563B1 (es)
EC (1) ECSP15007420A (es)
ES (1) ES2764381T3 (es)
GT (1) GT201500019A (es)
HR (1) HRP20192342T1 (es)
HU (1) HUE047781T2 (es)
IL (2) IL236844B (es)
LT (1) LT2877599T (es)
MX (2) MX370507B (es)
NI (1) NI201500004A (es)
NZ (4) NZ740700A (es)
PE (3) PE20150644A1 (es)
PH (2) PH12015500175A1 (es)
PL (1) PL2877599T3 (es)
PT (1) PT2877599T (es)
RS (1) RS59812B1 (es)
SG (2) SG11201500184TA (es)
SI (1) SI2877599T1 (es)
SM (1) SMT201900735T1 (es)
UA (1) UA118178C2 (es)
WO (1) WO2014018926A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721506C (en) 2008-04-16 2019-09-17 Jun Luo Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
AP2014007657A0 (en) 2011-12-16 2014-05-31 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
US10202653B2 (en) 2012-04-20 2019-02-12 Cepheid Compositions and methods for detecting markers associated with bladder cancer
EP2912194B1 (en) * 2012-10-26 2019-05-08 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
JP2016516005A (ja) 2013-02-25 2016-06-02 ノバルティス アーゲー 新規のアンドロゲンレセプター変異
JP2016513961A (ja) * 2013-03-06 2016-05-19 セファイド 膀胱癌を検出する方法
BR112015023098A2 (pt) 2013-03-14 2017-07-18 Univ Jefferson agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
US9808472B2 (en) 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
TN2016000137A1 (en) 2013-10-18 2017-10-06 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
EA037895B1 (ru) * 2014-02-05 2021-06-02 Лек Фармасьютикалз Д.Д. Твердые фармацевтические композиции антагонистов рецепторов андрогенов
EP3146081B1 (en) 2014-05-19 2020-10-28 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
WO2016033114A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
CN108882893A (zh) 2016-03-29 2018-11-23 豪夫迈·罗氏有限公司 操作用于接收分析物数据的接收器的方法，接收器和计算机程序产品
WO2017181161A1 (en) * 2016-04-15 2017-10-19 Predicine, Inc. Systems and methods for detecting genetic alterations
CN106405085B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法
CN106198985B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法
CN106290919B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法
CN106526185B (zh) * 2016-10-28 2018-03-30 拜尔康(天津)医药科技有限公司 用于检测去势抵抗性前列腺癌的elisa试剂盒及检测方法
DK3527210T3 (da) * 2016-12-16 2021-08-09 Kangpu Biopharmaceuticals Inc Kombineret sammensætning omfattende en benzoheterocyklisk forbindelse og en androgenreceptorvejsmodulator samt anvendelser deraf
WO2019077407A1 (en) * 2017-10-19 2019-04-25 Yale University INHIBITION OF THE ANDROGENIC RECEPTOR USING MEDICINAL PLANT EXTRACTS AND COMPOSITIONS THEREOF
CN108018342A (zh) * 2017-12-04 2018-05-11 合肥艾迪康临床检验所有限公司 检测ar基因突变的引物和方法
CN109115742A (zh) * 2018-09-05 2019-01-01 中国农业科学院农业质量标准与检测技术研究所 一种抗雄激素效应的检测方法
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
KR102473989B1 (ko) 2018-11-28 2022-12-07 (주)바이오니아 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물
US11420956B2 (en) * 2019-09-23 2022-08-23 Accutar Biotechnology Inc. Ureas having Androgen Receptor degradation activity and uses thereof
GB201914296D0 (en) * 2019-10-03 2019-11-20 Univ Oxford Innovation Ltd Treatment
WO2021110731A1 (en) * 2019-12-03 2021-06-10 Bayer Aktiengesellschaft Method for determining the response of prostate cancer patients to treatment with androgen receptor antagonists based on gene expression changes or super-enhancer protein-binding profiles
CN113533730B (zh) * 2021-07-23 2022-09-06 南方医科大学深圳医院 一种血浆外泌体标志物组合及其应用
WO2024001989A1 (en) * 2022-06-27 2024-01-04 Etern Biopharma (Shanghai) Co., Ltd. Compositions and methods for modulating molecules
CN117860773B (zh) * 2023-11-28 2024-07-16 四川大学华西医院 促进ar基因甲基化的药物及其在预防或治疗雄性激素脱发中的用途
CN117778322B (zh) * 2023-12-17 2025-02-07 苏州拓维生物技术有限公司 一种对恩杂鲁胺耐药的细胞系的筛选方法及其应用
CN119979543B (zh) * 2025-04-14 2025-07-22 羿美诚健(上海)生物医药有限公司 靶向雄激素受体的小核酸及其药物组合物和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5702890A (en) 1993-07-26 1997-12-30 K.O. Technology, Inc. Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents
US6200754B1 (en) 1998-03-19 2001-03-13 Variagenics, Inc. Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
GB0005689D0 (en) * 2000-03-09 2000-05-03 Schering Ag Crystal
BR0111298A (pt) * 2000-06-28 2005-05-10 Bristol Myers Squibb Co Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos
US7718684B2 (en) * 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
CN101932709B (zh) * 2007-11-26 2014-09-10 桑塔里斯制药公司 靶向雄激素受体的lna拮抗剂
EP2065474A1 (en) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
US8133724B2 (en) * 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
WO2010112581A1 (de) * 2009-04-03 2010-10-07 Basf Se Verfahren zur herstellung von kompositmaterialien
CN102573472A (zh) * 2009-10-23 2012-07-11 健康研究公司 治疗雄激素受体阳性癌症的方法

Also Published As

Publication number Publication date
NZ704487A (en) 2018-05-25
AU2019201726A1 (en) 2019-04-04
AU2017203385A1 (en) 2017-06-08
PL2877599T3 (pl) 2020-05-18
AU2013295543B2 (en) 2019-03-14
NZ742581A (en) 2020-02-28
KR20150072399A (ko) 2015-06-29
SG11201500184TA (en) 2015-04-29
DK2877599T3 (da) 2020-01-20
HUE047781T2 (hu) 2020-05-28
NZ744288A (en) 2020-04-24
NZ740700A (en) 2019-07-26
AU2017203385B2 (en) 2018-12-20
HRP20192342T1 (hr) 2020-04-03
PT2877599T (pt) 2020-01-24
ES2764381T3 (es) 2020-06-03
EA201792520A3 (ru) 2018-08-31
EA201792520A2 (ru) 2018-04-30
HK1211060A1 (en) 2016-05-13
PH12015500175B1 (en) 2015-03-16
KR102210183B1 (ko) 2021-01-29
SI2877599T1 (sl) 2020-03-31
RS59812B1 (sr) 2020-02-28
WO2014018926A8 (en) 2014-04-10
JP6297556B2 (ja) 2018-03-20
WO2014018926A1 (en) 2014-01-30
SG10201703254VA (en) 2017-06-29
PH12015500175A1 (en) 2015-03-16
EA029563B1 (ru) 2018-04-30
SMT201900735T1 (it) 2020-03-13
CN104685072A (zh) 2015-06-03
EA035535B1 (ru) 2020-07-01
MX2015001209A (es) 2015-09-23
CY1122651T1 (el) 2021-03-12
EA201590290A1 (ru) 2015-06-30
US20170196840A1 (en) 2017-07-13
MX2019015148A (es) 2020-02-19
BR122017017921A2 (pt) 2019-09-10
IL236844B (en) 2019-09-26
BR112015001801A2 (pt) 2017-11-07
CA2879926A1 (en) 2014-01-30
EP3653733A1 (en) 2020-05-20
JP2015531590A (ja) 2015-11-05
CL2015000194A1 (es) 2015-04-24
CN108048567A (zh) 2018-05-18
KR20210012064A (ko) 2021-02-02
MX370507B (es) 2019-12-16
JP6592545B2 (ja) 2019-10-16
PE20190574A1 (es) 2019-04-22
UA118178C2 (uk) 2018-12-10
CN110845626A (zh) 2020-02-28
PH12018502500A1 (en) 2020-09-14
CO7280477A2 (es) 2015-05-29
JP2020072655A (ja) 2020-05-14
PE20190845A1 (es) 2019-06-17
IL236844A0 (en) 2015-03-31
CR20150022A (es) 2015-04-30
IL265610B (en) 2021-03-25
US20150252426A1 (en) 2015-09-10
EP2877599A1 (en) 2015-06-03
LT2877599T (lt) 2020-01-27
IL265610A (en) 2019-05-30
US9617602B2 (en) 2017-04-11
EP2877599B1 (en) 2019-10-23
JP2018113968A (ja) 2018-07-26
AU2019201726B2 (en) 2021-04-01
NI201500004A (es) 2015-10-05
ECSP15007420A (es) 2016-01-29
GT201500019A (es) 2017-07-24
AU2013295543A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
PE20150644A1 (es) Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno
CL2015001508A1 (es) Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros.
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CO6680708A2 (es) Compuesto modulares de estrógenos y composiciones que comprenden los mismos
BR112014014124A2 (pt) Moduladores do receptor de estrogênio fluorados e usos dos mesmos
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
NI201500093A (es) Modulador del receptor de andrógenos y usos de este
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CL2013000732A1 (es) Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
MX2014011217A (es) Moduladores del receptor de estrogeno y sus usos.
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
BR112016005589B8 (pt) Composição farmacêutica líquida, e, uso da mesma
EA202090782A1 (ru) Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
UY32679A (es) Antagonistas policíclicos de receptores de ácido lisofosfatidico
CU20140058A7 (es) Nuevos 2h-indizoles como antagonistas del receptor ep-2

Legal Events

Date Code Title Description
FG Grant, registration